Xeris Biopharma Holdings, Inc.
XERS
$8.48
-$0.05-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.33% | 41.47% | 43.72% | 42.05% | 35.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.33% | 41.47% | 43.72% | 42.05% | 35.62% |
| Cost of Revenue | 3.05% | 12.19% | 15.58% | 17.68% | 47.96% |
| Gross Profit | 43.52% | 47.81% | 49.95% | 47.63% | 33.21% |
| SG&A Expenses | 19.95% | 13.23% | 11.56% | 8.76% | 13.24% |
| Depreciation & Amortization | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.80% | 13.84% | 12.77% | 10.24% | 17.04% |
| Operating Income | 472.56% | 259.63% | 173.99% | 121.70% | 73.59% |
| Income Before Tax | 51.41% | 125.20% | 100.97% | 76.16% | 40.21% |
| Income Tax Expenses | -- | -- | -- | 100.00% | -789.63% |
| Earnings from Continuing Operations | 46.36% | 126.64% | 101.01% | 75.22% | 46.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.36% | 126.64% | 101.01% | 75.22% | 46.28% |
| EBIT | 472.56% | 259.63% | 173.99% | 121.70% | 73.59% |
| EBITDA | 2,038.05% | 560.85% | 271.73% | 166.35% | 109.12% |
| EPS Basic | 54.68% | 123.75% | 99.47% | 76.50% | 49.57% |
| Normalized Basic EPS | 134.41% | 121.97% | 99.48% | 78.65% | 44.61% |
| EPS Diluted | 53.07% | 121.61% | 98.84% | 76.66% | 48.53% |
| Normalized Diluted EPS | 131.92% | 120.15% | 98.13% | 78.59% | 44.61% |
| Average Basic Shares Outstanding | 10.32% | 10.14% | 9.30% | 8.45% | 7.95% |
| Average Diluted Shares Outstanding | 16.09% | 16.01% | 14.08% | 10.87% | 7.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |